MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Did Legend Biotech's Investor Event Reveal About CARVYKTI

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Did the Recent CARVYKTI Data Reveal About Its Potential

1 months ago

What Did Bunge's 2026 Investor Day Reveal About Its Future

4 months ago

What Do Edesa Biotech's Latest Earnings Reveal About Its Trajectory

2 months ago

What Did Skillsoft's Q4 FY2026 Earnings Reveal About Its Trajectory

3 months ago

Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS

Kyverna Therapeutics is positioned to pioneer autoimmune CAR T with miv-cel, targeting FDA approval by late 2026 after regulatory alignment for a rolling BLA submission in SPS. The company holds $236M...

CAR

Stock News•1 months ago

Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use

Legend Biotech highlighted long-term clinical data and physician support for CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma. The company aims to expand the drug's use into earlier...

LEGN

Stock News•1 months ago

A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals

A China-focused tech fund has initiated a position in Legend Biotech, a developer of cell therapies for hematologic malignancies and solid tumors. This move signals potential institutional interest in...

LEGN

Stock News•2 months ago

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results

Legend Biotech (NASDAQ:LEGN) shares may face pressure after the company reported downbeat financial results for the first quarter on Tuesday. Analysts have begun revising their forecasts downward foll...

LEGN